<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">
Blogs

CU Cancer Center News and Stories

Leukemia

Community    Blood Cancer    Leukemia    Multiple Myeloma

The Latest on CAR T-Cell Therapy

September is Blood Cancer Awareness Month, a time for bringing attention to leukemia, lymphoma, myeloma, Hodgkin’s disease, and other blood cancers.


Author Greg Glasgow | Publish Date September 16, 2022
Full Story

Research    Pediatric Cancer    Blood Cancer    Leukemia    Clinical Trials

St. Baldrick’s Funds CU Study of New Pediatric Leukemia Drug 

As part of its ongoing efforts to eradicate childhood cancers, the St. Baldrick’s Foundation has awarded University of Colorado Cancer Center member Kelly Faulk, MD, a St. Baldrick’s Scholar grant to investigate a new method for treating infant leukemia


Author Greg Glasgow | Publish Date September 08, 2022
Full Story

Research    Blood Cancer    Leukemia

New Research Grant Underscores the CU Cancer Center’s Long Relationship With the Leukemia & Lymphoma Society 

In research that reinforces the University of Colorado Cancer Center’s longstanding relationship with the Leukemia & Lymphoma Society (LLS), CU Cancer Center member Lauren Nicholas, PhD, MPP, is co-principal investigator on a new LLS-funded study to examine the role of Medicare plan selection in dealing with a blood cancer diagnosis.  


Author Greg Glasgow | Publish Date August 30, 2022
Full Story

Community    Leukemia    Clinical Research    Drug Development

Presentation to Colorado Legislature Committee Will Highlight Breakthrough Research in Leukemia Treatment

University of Colorado (CU) Cancer Center researchers have been on the leading edge of developing new therapies for leukemia. One of the most recent breakthrough therapies has been the development of venetoclax, a B-cell lymphoma-2 inhibitor, that that has shown profound results for adults with acute myeloid leukemia (AML) and has become a standard of care for patients with this disease all over the world.


Author Rachel Sauer | Publish Date February 24, 2022
Full Story

Research    Pediatric Cancer    Leukemia

CU Cancer Center Member M. Eric Kohler, MD, PhD, Receives Award to Develop Immunotherapy Treatment for Pediatric Leukemia

University of Colorado Cancer Center member M. Eric Kohler, MD, PhD, was awarded a three-year, $270,650 Young Investigator Grant from CureSearch for Children’s Cancer, in partnership with the SebastianStrong Foundation, to develop a new treatment approach for acute myeloid leukemia (AML), a rare blood cancer in children.


Author Greg Glasgow | Publish Date September 17, 2021
Full Story

Patient Care    Blood Cancer    Leukemia

Norm MacDonald’s Death Puts Spotlight on Acute Leukemia

Comedian and former “Saturday Night Live” cast member Norm MacDonald died Tuesday, after what his brother, Neil MacDonald, described as a nine-year battle with acute leukemia. Norm MacDonald, known for his intelligence and sarcastic wit, was 61.


Author Greg Glasgow | Publish Date September 16, 2021
Full Story

Patient Care    Blood Cancer    Leukemia    Magazine    Clinical Trials

Acute Myeloid Leukemia (AML) Won’t Slow World Champion Triathlete Down

Siri Lindley couldn’t swim. She had never learned how and the idea of competing in a triathlon seemed completely out of the question.


Author Cancer Center | Publish Date May 16, 2021
Full Story

Research    Patient Care    Pediatric Cancer    Blood Cancer    Leukemia    Magazine

CU Cancer Center Researcher and Physician Poses Double Threat to Pediatric Cancer

M. Eric Kohler’s commitment to both cancer research — particularly CAR T-cell therapy — and clinical care make him a double threat when it comes to battling pediatric blood cancer.   


Author Valerie Gleaton | Publish Date March 26, 2021
Full Story

Research    Blood Cancer    Leukemia    Magazine

CU Cancer Center Leukemia Researcher Receives NCI Outstanding Investigator Award

Craig Jordan, PhD, has spent more than 20 years developing better treatments for acute myeloid leukemia (AML), a rapidly progressing cancer of the blood and bone marrow that can spread to other parts of the body, including the lymph nodes, liver, spleen and central nervous system.


Author Greg Glasgow | Publish Date November 23, 2020
Full Story

Research    Blood Cancer    Leukemia    Magazine

CU Cancer Center study leads to FDA approval of new treatment for AML

Thanks in large part to early work by investigators at the CU Cancer Center, patients with acute myeloid leukemia (AML) have a new treatment option that has fewer side effects and has been shown to increase longevity.


Author Cancer Center | Publish Date November 10, 2020
Full Story

Patient Care    Community    Faculty    Leukemia

Getting to the Root of Leukemia

The day before Joel Rutstein planned to leave for a week-long trip to Hawaii with his wife, Barbara, and their grown children, an oncologist in Fort Collins gave Joel bad news.


Author Garth Sundem | Publish Date January 03, 2019
Full Story

Patient Care    Leukemia    Clinical Trials

91 Percent Response Rate for Venetoclax Against Newly Diagnosed AML in Older Adults

Clinical trial results published in the journal Nature Medicine show 91 percent response rate to the combination of venetoclax with azacitidine in older adults newly diagnosed with acute myeloid leukemia (AML). Of 33 patients given combination venetoclax and azacitidine, 20 experienced a complete response (aka complete remission) and eight experienced a complete response but with continued low blood counts. Of the three patients who did not respond to treatment, two discontinued the study before the first week due to personal reasons unrelated to treatment or side-effects.


Author Garth Sundem | Publish Date November 29, 2018
Full Story

Research    Leukemia    Cancer

Cancer Hijacks the Microbiome to Glut Itself on Glucose

Cancer needs energy to drive its out-of-control growth. It gets energy in the form of glucose, in fact consuming so much glucose that one method for imaging cancer simply looks for areas of extreme glucose consumption – where there is consumption, there is cancer. But how does cancer get this glucose? A University of Colorado Cancer Center study published today in the journal Cancer Cell shows that leukemia undercuts the ability of normal cells to consume glucose, thus leaving more glucose available to feed its own growth.


Author Garth Sundem | Publish Date September 28, 2018
Full Story

CU Cancer Center In the News

Biospace

ODAC Votes Against Safety Profile of Secura Bio’s P13K Inhibitor

news outletBiospace
Publish DateSeptember 26, 2022

In an 8-4 vote, the FDA’s Oncologic Drugs Advisory Committee Roster voted against the benefit-risk profile of Secura Bio’s P13K inhibitor Copiktra.

Full Story
Cancer Health

Abortion Ban Will Harm Women Diagnosed with Breast Cancer During Pregnancy

news outletCancer Health
Publish DateSeptember 22, 2022

Two CU Cancer Center members detail how the Supreme Court decision in Dobbs V. Jackson Women’s Health Organization will harm some patients.

Full Story
ET Healthworld

Researchers Discover New Imaging Information System May Provide Accurate Prognosis for Certain Cancers

news outletET Healthworld
Publish DateSeptember 20, 2022

A novel imaging information system developed by researchers at CU Anschutz may eventually provide a faster, more accurate prognosis for certain tumors.

Full Story
Cancer Health

Researchers Find Less Risky Way to Monitor Breast Cancer Progression

news outletCancer Health
Publish DateSeptember 20, 2022

CU Cancer Center researchers have discovered how to extract critical information about breast cancer tumors and disease progression by analyzing blood plasma.

Full Story